ClinicalTrials.gg
RecruitingNCT05434819SAFEUpdated Oct 5, 2026

Surgical Ablation of AF Efficacy Trial

An interventional study of Surgical Atrial Fibrillation Ablation in Atrial Fibrillation and Heart Failure, sponsored by Population Health Research Institute. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Population Health Research Institute · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Atrial Fibrillation by Population Health Research Institute — 6 open to participants now, 6 under way, 1 of them phase 3. Atrial Fibrillation · Population Health Research Institute.

Planned enrollment
7th of 24
2,000 · median 300
Started
2023
the only one that year
No phase
7 of 30
2 open now
Registered
25th of 30
by date

Among the 30 studies in Atrial Fibrillation by Population Health Research Institute, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 7 with no phase, and was the 25th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 30 studies in Atrial Fibrillation by Population Health Research Institute are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Atrial Fibrillation by Population Health Research Institute, or all of them as a file.
02

Study summary

SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.

Read the detailed description

Atrial fibrillation (AF) affects more than 1% of the general population and is an important risk factor for stroke. AF prevalence increases with age, occurring in 10 to 15% of patients older than 80 years of age, which is important with the aging population. Of patients undergoing cardiac surgery, 10.8% have a history of AF. AF is believed to cause the left atrium to dilate and lose its transport function. AF significantly increases the risk of ischemic stroke of cardioembolic origin, but is also associated with heart failure and impairs quality of life. Although the causal relationship between the 2 clinical entities has not been fully elucidated, AF is believed to cause heart failure via several mechanisms.

Ablation of AF is the application of scars to the atrial tissue to disrupt faulty electrical signals that cause the arrhythmia. If surgical ablation of AF yields a benefit similar to catheter-based AF ablation, thousands of people undergoing cardiac surgery could benefit from this procedure each year. SAFE will be a landmark trial in cardiac surgery, definitely establishing surgical AF ablation's impact on cardiovascular outcomes. Cardiac surgery is the optimal setting to establish whether maintenance of sinus rhythm through AF ablation yields clinical benefit, and is a setting where sham-control is possible. This will not only provide evidence for the cardiac surgical patients but will bolster the evidence for ablation (catheter or stand-alone surgical) in other AF patients.

The intervention under investigation is concomitant surgical AF ablation which is compared to no surgical AF ablation. The primary outcome is hospital readmissions with heart failure during 4 years of follow-up. This study will enroll 2000 patients from 50 centres, globally. Patients will be followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals until the final follow-up visit, for a median follow-up for 4 years.

03

Conditions studied

  • Atrial Fibrillation
  • Heart Failure

Keywords

  • Surgical Ablation
  • Cardiac Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Undergoing a clinically indicated cardiac surgical procedure: CABG, AVR, ascending aorta replacement, or combinations thereof;
  • Documented history of paroxysmal or persistent AF
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Dominant atrial arrhythmia is atrial flutter;
  • Documented left atrial diameter ≥ 6 cm;
  • Previous cardiac surgery requiring opening of the pericardium;
  • Patients undergoing any of the following procedures:

    1. Heart transplant
    2. Complex congenital heart surgery
    3. Sole indication for surgery is ventricular assist device insertion
    4. Mitral valve repair or replacement
    5. Tricuspid valve repair or replacement
  • Patient resides in a long-term care facility
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Surgical Atrial Fibrillation Ablation Group

    Surgeon will perform left atrial ablation during patient's cardiac surgery procedure.

    Procedure: Surgical Atrial Fibrillation Ablation

  • No intervention
    No Surgical Atrial Fibrillation Ablation Group

    Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure.

Interventions

  • ProcedureSurgical Atrial Fibrillation Ablation

    Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.

06

What researchers measure

Primary outcomes

  1. Number of hospital readmissions for heart failure over duration of follow-up

    Total number of hospital readmissions for heart failure.

    Time frame: Common termination point for trial (median follow-up of 4 years)

Secondary outcomes

  1. Number of Ischemic stroke or systemic arterial embolism events over duration of follow up

    Number of Ischemic stroke or systemic arterial embolism events over duration of follow up

    Time frame: Common termination point for trial (median follow-up of 4 years)

  2. Length of ICU stay

    Length of ICU stay, including readmissions, from study intervention surgery to hospital discharge, including readmissions

    Time frame: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

  3. Length of hospital stay

    Length of hospital stay

    Time frame: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

  4. Freedom from recurrence of atrial tachyarrhythmia

    Freedom from recurrence of atrial tachyarrhythmia

    Time frame: 1 year post-operatively

  5. Number of days free from admission to healthcare facility or presentation to the emergency department for heart failure

    Number of days free admission to healthcare facility or presentation to the emergency department for heart failure

    Time frame: Common termination point for trial (median follow-up of 4 years)

  6. All-cause mortality

    All-cause mortality

    Time frame: Common termination point for trial (median follow-up of 4 years)

  7. Cardiovascular mortality

    Cardiovascular mortality

    Time frame: Common termination point for trial (median follow-up of 4 years)

  8. Antiarrhythmic drug use

    Antiarrhythmic drug use

    Time frame: Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)

  9. Number of patients undergoing atrial fibrillation ablation

    Number of patients undergoing atrial fibrillation ablation

    Time frame: 90 days post- study surgery until common termination point for trial (median follow-up of 4 years)

  10. Quality of Life - atrial fibrillation specific

    Atrial fibrillation specific quality of life as assessed by the Atrial Fibrillation Effect on QualiTy of Life questionnaire (AFEQT) which is 20 questions using a 7 point Likert scale where a higher score means a worse outcome.

    Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)

  11. Quality of Life - heart failure specific

    Heart failure specific quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) which is a 12 questions using Likert scales where a higher score is a better outcome.

    Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)

  12. Quality of Life - General

    Quality of life- general as assessed by the European quality of life index version 5D (EQ-5D-5L) which consists of a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Other outcomes

  1. Number of Ischemic stroke and systemic arterial embolism

    Safety outcome

    Time frame: Up to 30 days post-operatively

  2. Number of patients requiring permanent pacemaker implantation

    Safety outcome

    Time frame: Up to 1 year post-operatively

  3. Volume of chest tube output

    Safety outcome - chest tube output measured in mL.

    Time frame: Up to 24 hours post-operatively

  4. Re-operation for bleeding

    Safety outcome

    Time frame: From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

  5. All-cause mortality

    Safety outcome

    Time frame: Prior to discharge or within 30 days post-operatively (whichever occurs first)

  6. Post-operative major bleeding

    Safety outcome

    Time frame: <48 hours after surgery

  7. Number of patients with pulmonary vein stenosis

    Safety outcome

    Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)

  8. Number of patients with stiff left atrium syndrome

    Safety outcome

    Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)

  9. Number of patients with esophageal to atrial fistula

    Safety outcome

    Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)

  10. Health economic analysis of surgical atrial fibrillation

    Economic analysis will be assessed via health care utilization by patients

    Time frame: At 1 year, and at common termination point (median follow-up of 4 years)

  11. Health economic analysis of surgical atrial fibrillation

    Economic analysis will be assessed via a questionnaire of health care visits and costs incurred by patients.

    Time frame: At 1 year, and at common termination point (median follow-up of 4 years)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Sep 2027, 51 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 51 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
Jun 28, 2022
StartActual
Jun 1, 2023
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 30, 2027
Oct 5, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05434819
Responsible party
Richard Whitlock (Professor of Surgery, Population Health Research Institute) — Principal investigator
First posted
Jun 28, 2022
Start date
Jun 1, 2023
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Richard Whitlock
Contact
Richard.Whitlock@phri.ca
905-521-2100
SAFE Coordinators
Contact
SAFE@phri.ca
Richard Whitlock
principal investigator · Population Health Research Institute
Emilie Belley-Côté
principal investigator · Population Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion